A Rare STRN-ALK Fusion in Lung Adenocarcinoma Identified Using Next-Generation Sequencing–Based Circulating Tumor DNA Profiling Exhibits Excellent Response to Crizotinib

The ALK gene fusion has been identified as a new driver gene in non–small cell lung cancer (NSCLC). It includes the EML4-ALK rearrangement as a recurring event that renders the tumor sensitive to ALK tyrosine kinase inhibitor crizotinib. In addition, several other fusion partners to ALK kinase domai...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yan, Qin, Shu-Kui, Zhu, Jian, Wang, Rui, Li, Yu-Mei, Xie, Zong-Yu, Wu, Qiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134903/
https://www.ncbi.nlm.nih.gov/pubmed/30225407
http://dx.doi.org/10.1016/j.mayocpiqo.2017.04.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134903/
https://www.ncbi.nlm.nih.gov/pubmed/30225407
http://dx.doi.org/10.1016/j.mayocpiqo.2017.04.003

Ejemplares similares